Brief: NLS Pharmaceutics And Kadimastem Unveil Multi-Target Approach To Diabetes
10/02/2025 13:43
Feb 10 (Reuters) - Kadimastem KDST.TA :
* NLS PHARMACEUTICS AND KADIMASTEM UNVEIL MULTI-TARGET
APPROACH TO
DIABETES, EXPANDING BEYOND GLP-1 THERAPIES
Source text: ID:nPn4kTQGna
Further company coverage: KDST.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing